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E-mail: alan.melcher@icr.ac.ukA clinical oncolytic herpes simplex virus (HSV) encoding
granulocyte-macrophage colony-stimulating factor (GM-
CSF), talimogene laherparepvec, causes regression of injected
and non-injected melanoma lesions in patients and is now
licensed for clinical use in advanced melanoma. To date,
limited data are available regarding the mechanisms of human
anti-tumor immune priming, an improved understanding of
which could inform the development of future combination
strategies with improved efﬁcacy. This study addressed direct
oncolysis and innate and adaptive human immune-mediated
effects of a closely related HSV encoding GM-CSF (HSVGM-CSF)
alone and in combination with histone deacetylase inhibition.
We found that HSVGM-CSF supported activation of anti-
melanoma immunity via monocyte-mediated type I interferon
production, which activates NK cells, and viral maturation of
immature dendritic cells (iDCs) into potent antigen-presenting
cells for cytotoxic T lymphocyte (CTL) priming. Addition of
the histone deacetylase inhibitor valproic acid (VPA) to
HSVGM-CSF treatment of tumor cells increased viral replication,
viral GM-CSF production, and oncolysis and augmented the
development of anti-tumor immunity. Mechanistically, VPA
increased expression of activating ligands for NK cell recogni-
tion and induced expression of tumor-associated antigens, sup-
porting innate NK cell killing and CTL priming. These data
support the clinical combination of talimogene laherparepvec
with histone deacetylase inhibition to enhance oncolysis and
anti-tumor immunity.
INTRODUCTION
Oncolytic viruses (OVs) are naturally occurring or genetically engi-
neered viruses with speciﬁc anti-tumor effects mediated both by
direct oncolysis and activation of innate and adaptive anti-tumor im-
munity. A range of OVs has progressed to clinical studies, and some
viruses (e.g., herpes simplex, vaccinia, and reovirus) have reached
evaluation in randomized clinical trials.1 The most clinically
advanced agent (approved for use in the United States, Europe, andThis is an open access article undeAustralasia) is a genetically modiﬁed double-stranded DNA herpes
simplex virus (HSV; JS-1 strain) called talimogene laherparepvec
(T-Vec). This virus has been rendered tumor-selective through func-
tional deletion of ICP34.5; further deletion of ICP47 enhances antigen
presentation and brings the viral US11 gene under the control of the
ICP47 immediate-early promoter, enhancing tumor-selective replica-
tion.2 In addition, the ICP34.5 gene has been replaced with a cassette
encoding human GM-CSF to facilitate priming of an anti-tumor im-
mune response,3 and an initial clinical report has conﬁrmed that the
virus can convert an immunologically suppressive “cold” tumor
microenvironment (TME) into an immune-activating “hot” milieu.4
Hence, T-Vec has a dual mode of action, causing direct tumor cell
lysis and bystander activation of an anti-tumor immune response.
Following a phase I study demonstrating acceptable toxicity,5 phase II
testing of intratumoral T-Vec in patients with advanced melanoma
resulted in a 26% response rate, with durable responses observed in
both injected and uninjected lesions.6 Distant responses suggested
generation of anti-tumor immunity, which was consistent with exper-
iments showing an increase in melanoma-associated antigen-speciﬁc
T cells and a decrease in suppressive T cells in tumors after treat-
ment.7 These encouraging clinical trial data led to a randomized
phase III study in melanoma, comparing intratumoral injection
against subcutaneous GM-CSF,8 which achieved its primary endpoint
of durable response rate.9 Early clinical trials also demonstrated that
T-Vec was present in the blood and uninjected lymph nodes as well as
in the injected tumor,5,10 suggesting that viral systemic immune acti-
vation and priming instigated within the directly targeted TME mayMolecular Therapy Vol. 27 No 6 June 2019 ª 2019 The Authors. 1
r the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. HSVGM-CSF Induces Innate and Adaptive Anti-tumor Immunity
(A) Healthy donor PBMC (with or without HSVGM-CSF treatment) were co-cultured with melanoma targets, and NK cell (CD56+/CD3) CD107 degranulation was determined
by flow cytometry. The mean percentage of NK cells degranulating after co-culture with MEL888, A375, and MeWo tumor cell targets + SEM is shown (at least n = 4). (B)
PBMCs frommelanoma patients withmetastatic disease (with or without HSVGM-CSF treatment) were co-cultured withmelanoma targets (MEL888 cells), and NK cell (CD56+/
CD3) CD107 degranulation was determined by flow cytometry. Themean percentage of NK cells expressing CD107 + SEM is shown (n = 4). (C) Healthy donor PBMCs (with
(legend continued on next page)
Molecular Therapy
2 Molecular Therapy Vol. 27 No 6 June 2019
Please cite this article in press as: Jennings et al., Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase
Inhibition, Molecular Therapy (2019), https://doi.org/10.1016/j.ymthe.2019.04.008
www.moleculartherapy.org
Please cite this article in press as: Jennings et al., Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase
Inhibition, Molecular Therapy (2019), https://doi.org/10.1016/j.ymthe.2019.04.008play an additional role in bystander immune-mediated therapy.
Randomized trials testing a combination of T-Vec with immune
checkpoint inhibitors in melanoma have now been completed, with
early results showing signiﬁcant promise.4,11
Despite this clinical progress, pre-clinical data on the mechanisms
responsible for the therapeutic potential of T-Vec are relatively
limited, and further information would inform the development of
future combination therapies. One promising strategy is to combine
OVs with histone deacetylase (HDAC) inhibitors (HDACIs), which
regulate chromatin structure and gene transcription. Histone acetyla-
tion is regulated by the opposing actions of histone acetyltransferases
(HATs), which mediate the acetylation of histone residues allowing
gene transcription, whereas HDACs remove acetyl groups, allowing
the negatively charged DNA to bind the nucleosome, acting as tran-
scriptional repressors. HDACs are classiﬁed into four different sub-
classes based on their sequence homology and structural similarity:
class I HDACs (HDAC1, HDAC2, HDAC3, and HDAC8), class II
HDACs (HDAC4, HDAC5, HDAC7, HDAC9, and HDAC10), class
III HDACs (sirtuins), and a class IV HDAC (HDAC11). High expres-
sion of class I and II HDACs has been associated with poor patient
outcome, and HDACIs have been developed as anticancer agents.
HDAICs induce a diverse range of biological responses in tumors,
including apoptosis, suppressed proliferation of malignant cells, inhi-
bition of angiogenesis, and immunomodulation.12–15 Speciﬁcally, in
terms of immunomodulation, HDACIs have been reported to
increase antigen presentation (through modulation of major histo-
compatibility complex [MHC] molecules), increase T cell recogni-
tion, increase natural killer (NK) cell-activating ligand expression
and NK cell-mediated killing, increase ICAM-1 expression to pro-
mote leukocyte inﬁltration, enhance immunological synapse forma-
tion between T cells and antigen-presenting cells (APCs), and
decrease levels of regulatory T cells (Tregs).13
Clinically, HDACIs have gained Food and Drug Administration
(FDA) approval for the treatment of cancer, including vorinostat
and FK228 for the treatment of cutaneous T cell lymphoma
(CTCL), belinostat for the treatment of peripheral T cell lymphoma
(PTCL), and panobinostat, in combination with bortezomib and
dexamethasone for the treatment of multiple myeloma. Although
most HDACIs have been approved for the treatment of hematological
malignancies, numerous studies and clinical trials have examined
their activity against solid malignancies, such as ovarian and breast
cancer.14 Valproic acid (VPA), an anticonvulsant agent and more
recently described HDACI with speciﬁcity toward class I and classor without HSVGM-CSF) were co-cultured withMEL888, A375, andMeWo cell targets, and
the mean of at least three experiments ± SEM. (D) Immature dendritic cells were treated w
ABC, and HLA-DR/DP/DQ was determined by flow cytometry. Representative histogr
controls + SEM (bottom panel) are shown (n = 4). (E) Supernatants frommelanoma cells t
concentrations of GM-CSF, IL-10, and TNF-a were determined by ELISA. The graph s
primed CTLs) or treated with 0.1 PFUs/cell HSVGM-CSF (Mel888+HSV-GM-CSF-primed
cultured with autologous PBMCs. CTLs were re-stimulated once (as appropriate) and t
targets. The graph shows the mean percentage of tumor cell death ± SEM (n = 3). StaIIa HDACs, has also been reported to display anticancer properties
through induction of cell differentiation, inhibition of cell prolifera-
tion, and/or altered immunogenicity. VPA acts by directly inhibiting
HDACs but also induces proteasomal degradation of HDAC2,
exerting its anticancer properties by both transcription-dependent
and transcription-independent mechanisms. Currently, VPA is not
FDA-approved for the treatment of cancer; however, it has been
studied extensively in pre-clinical models and has reached phase III
clinical testing for cervical and ovarian cancer.15 Pivotally, VPA is
an approved treatment option for epilepsy, bipolar disorder, and
migraine prevention and has a well-established safety proﬁle derived
from decades of clinical use. Moreover, VPA is a cost-effective treat-
ment option in comparison with newer HDACIs, making re-purpos-
ing this agent an attractive option for the treatment of cancer.15
HDACIs, including VPA, have been successfully tested in combina-
tion with OVs,16,17 and a range of synergistic mechanisms have
been identiﬁed, including (1) suppression of anti-viral interferon
(IFN)-responsive gene transcription, leading to increased viral repli-
cation, spread, and oncolysis/apoptosis; (2) induction of nuclear fac-
tor kB (NF-kB) signaling, resulting in NF-kB-dependent autophagy;
(3) increased viral entry receptor expression and viral entry; (4) abro-
gation of innate immune-mediated viral clearance; and (5) enhance-
ment of adaptive anti-tumor immune responses through enhanced
CD8 T cell and macrophage inﬁltration and decreased Tregs, with
appropriate combination scheduling.18–20 To date, VPA has been re-
ported to enhance HSV and parvovirus replication in cancer cells,16,21
but its efﬁcacy in combination with HSV for melanoma has not been
described; moreover, the effect of VPA in OV-induced human immu-
notherapy remains unknown. Here we describe the use of clinically
relevant human models22–26 to explore oncolytic HSVGM-CSF and
VPA immune co-operation to support the development of anti-tu-
mor immune responses against human melanoma.
RESULTS
HSVGM-CSF Induces Innate and Adaptive Anti-tumor Immunity
We previously developed in vitro pre-clinical assays to test the poten-
tial of OVs to support the activation of human innate (dendritic cells
[DCs] and NK cells) and adaptive (cytotoxic T lymphocytes [CTLs])
anti-tumor immunity.22,24–26 To initially address the immunogenicity
of HSVGM-CSF, we pulsed the virus onto peripheral blood mononu-
clear cells (PBMCs) taken from healthy donors and melanoma pa-
tients and examined activation of NK cells. Addition of HSVGM-CSF
induced NK cell degranulation (release of cytotoxic granules) in
both healthy donor (Figure 1A) and patient samples (Figure 1B)the percentage of tumor cell lysis was determined by 51Cr release. The graph shows
ith or without HSVGM-CSF for 48 h, and cell surface expression of CD86, CD80, HLA-
ams (top panel) and the mean fold increase in expression compared with isotype
reated with or without HSVGM-CSF and co-cultured with iDCswere collected, and the
hows the mean + SEM (n = 3). (F) MEL888 cells were either left untreated (Mel888-
CTLs) and cultured with iDCs for 24 h before non-adherent cells were removed and
hen used in 4-h 51Cr release assays against MEL888 (relevant) or MCF-7 (irrelevant)
tistical significance is denoted by *p < 0.05, **p < 0.01, and p*** < 0.005.
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by increased expression of CD107 on NK cells. Importantly,
HSVGM-CSF-induced NK cell degranulation correlated with increased
lysis of melanoma cell targets (Figure 1C). To conﬁrm that NK cells
were responsible for melanoma target cell death, in the context of
PBMCs, we have shown that (1) depletion of NK cells from PBMCs
signiﬁcantly reduced killing of MEL888 cells (Figure S1A) and (2)
that killing was mediated by perforin and granzyme (pivotal compo-
nents of NK cell cytotoxic granules) because cell lysis was abrogated
by EGTA, a calcium chelator that prevents the activity of calcium-
dependent perforin (Figure S1B).
Having shown previously that OVs can activate DCs, pivotal APCs
that bridge both the innate and adaptive arms of the immune
system,22 we investigated the effect of HSVGM-CSF on the DC anti-
gen-presenting machinery (MHC class I and II) and co-stimulatory
molecules (CD80 and CD86). We found that HSVGM-CSF induced
maturation of immature DCs (iDCs), causing signiﬁcant upregulation
of CD80 and CD86 and retention of MHC class I and II (Figure 1D)
without signiﬁcantly decreasing cell viability (data not shown). Next,
to determine whether iDCs were infected with HSVGM-CSF and
whether this was required to induce DC maturation, we treated
iDCs with GFP-expressing HSV (0.01 and 0.1 plaque-forming units
[PFUs]/cell) and examined CD86 expression in GFP-positive
(HSV-infected) and GFP-negative (non-infected) DCs. At the highest
MOI, approximately 10% of DCs were GFP-positive, and in accor-
dance with this, a 10% loss in viability was observed, demonstrating
that DCs were indeed permissive to HSV infection and subsequent
cell death (data not shown). However, importantly, CD86 upregula-
tion was observed in GFP-negative DCs, suggesting an indirect mech-
anism of DC maturation, potentially mediated by cytokine release
(data not shown).
Furthermore, co-culture of HSVGM-CSF-infected tumor cells with
iDCs resulted in increased secretion of GM-CSF and tumor necrosis
factor alpha (TNF-a), together with decreased production of the
immunosuppressive cytokine interleukin-10 (IL-10) (Figure 1E); vi-
rus-infected melanoma cells secrete GM-CSF, as expected (Figure 3);
therefore, it is most likely that the GM-CSF production is derived
from infected tumor cells. However, given that up to 10% of DCs
can be infected by HSV, it is also possible that DCs may contribute
to GM-CSF production. Moreover, MEL888 cells secrete IL-10, which
can be downregulated by OV treatment,27 and iDCs produce TNF-a
following OV treatment;28 therefore, although we have not specif-
ically demonstrated that the changes in IL-10 and TNF-a levels are
due to effects on MEL888 cells and iDCs, respectively, we postulate
that this is the most likely explanation.
Finally, to assess whether HSVGM-CSF-induced DC maturation and
changes in the pro-inﬂammatory cytokine milieu supported adaptive
CTL immune priming, we loaded iDCs with HSVGM-CSF-infected
tumor cells and examined whether tumor-loaded DCs could support
the generation of tumor-speciﬁc CTLs.22,24,26 Figure 1F shows that
virus-infected tumor cells supported the generation of melanoma-4 Molecular Therapy Vol. 27 No 6 June 2019speciﬁc CTLs whereas non-infected tumor cells did not. Taken
together, these data show that HSVGM-CSF has the potential to
enhance both innate and adaptive anti-tumor immune responses.
Activation of a Human Innate ImmuneResponse byHSVGM-CSF Is
Dependent on Virus-Induced Type I IFN Production
To characterize the mechanisms responsible for innate NK cell activa-
tion following HSVGM-CSF treatment, we ﬁrst examined the ability of
HSVGM-CSF to activate isolatedNK cells. NK cells isolated fromPBMCs
and subsequently treated with HSVGM-CSF directly were unable to de-
granulate against melanoma targets and showed no upregulation of
the early activation marker CD69 (Figure 2A). Furthermore, when
PBMCs were depleted of CD14+ monocytes (shown previously to be
central to the immune response induced by an alternative OV,
reovirus24), we found that HSVGM-CSF treatment did not result in acti-
vation of NK cells, as assessed by surface CD69 expression, relative to
intact PBMCs, which included monocytes (Figure S2A); additionally,
NK cell-mediated killing was also signiﬁcantly abrogated (Figure S2B).
Therefore, these data support a role for monocytes within PBMCs in
mediating the activation of NK cells by HSVGM-CSF.
Upon further examination, we demonstrated that PBMCs treated with
HSVGM-CSF secreted type I, II, and III IFNs (Figure 2B) and that
blockade of type I IFNa/b abrogated HSVGM-CSF-induced activation
of NK cells in terms of CD69 expression (Figure 2Ci), NK cell CD107
degranulation (Figure 2Cii), and cytotoxicity against melanoma cells
(Figure 2Ciii). Furthermore, type I IFN production, like NK cell activa-
tion,was signiﬁcantly abrogatedwhenCD14+monocytesweredepleted
from PBMCs (Figure 2D). Taken together, these data show that the
innate response of NK cells followingHSVGM-CSF treatment of PBMCs
wasdependenton type I IFNproduction andconﬁrmeda role ofCD14+
monocytes in mediating type I IFN secretion.
HDAC Inhibition Enhances HSVGM-CSF Replication, Killing, and
GM-CSF Production in Melanoma Cells
Having shown that HSVGM-CSF induces innate and adaptive immune
responses in our human model systems, we subsequently examined
the ability of HDACIs to potentiate HSVGM-CSF efﬁcacy in terms of
direct cytotoxicity and HSVGM-CSF-induced anti-tumor immunity.
First, to investigate the direct cytopathic effects of HSVGM-CSF in
the presence or absence of HDACIs, MEL888 cells were pre-treated
with a range of HDACIs (VPA, tubastatin, vorinostat, droxinostat,
givinostat, and mocetinostat) for 24 h before addition of HSVGM-CSF
(at concentrations of up to 2.5 PFUs/cell) for a further 48 h, and cell
viability was determined by microculture tetrazolium test (MTT)
(Figure S3). These data demonstrated that all HDACIs tested were
able to enhance HSVGM-CSF cytotoxicity, although, as expected, the
results were variable, and the greatest potentiation was observed for
VPA, givinostat, and mocetinostat. Given the long-standing safety
proﬁle of VPA and the cost-effective nature of this agent, VPA was
selected for further experimentation.
Initially, the ability of VPA to potentiate HSVGM-CSF cytotoxicity
against a larger panel of melanoma cell lines was examined. All cells
Figure 2. Innate Activation Is Dependent on Type I IFNs and CD14+ Monocytes
(A) Healthy donor PBMCs or isolated NK cells were treated with HSVGM-CSF for 48 h andNK cell (CD56+/CD3) (i) CD69 expression and (ii) CD107 degranulation (following co-
culture with melanoma targets) were determined by flow cytometry (n = 4). (B) Healthy donor PBMCs were treated with HSVGM-CSF for 48 h, and production of IFNg, IFNa,
IFNb, and IL-29was determined by ELISA. The graph shows themean of at least four independent experiments + SEM. (C) Healthy donor PBMCswere treated overnight with
HSVGM-CSF either alone or in the presence of IFNa/b blocking antibodies or isotype controls before (i) CD69 upregulation on CD56+/CD3 NK cells was determined by flow
cytometry. The graph shows the average percentage of NK cells expressing CD69 + SEM (n = 3). (ii) PBMCs (with or without IFN blockade and with or without HSVGM-CSF)
were co-cultured with MEL888 cells, and NK cell CD107 degranulation was determined by flow cytometry. The graph shows the mean percentage of NK cells expressing
CD107a/b + SEM (n = 3). (iii) PBMCs (with or without IFN blockade and with or without HSVGM-CSF) were co-cultured with MEL888 cells at the indicated E:T ratios, and the
percentage of tumor cell lysis was determined by 51Cr release. The graph shows themean percentage lysis ±SEM (n = 3). (D) IFNa/b production fromwhole PBMCs or CD14+
monocyte-depleted PBMCs was determined by ELISA. The graph shows the mean + SEM (n = 5). Statistical significance is denoted by *p < 0.05, **p < 0.01, ***p < 0.005,
and ****p < 0.0001.
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Figure 3. VPA Enhances HSVGM-CSF-Induced
Cytotoxicity, Viral Replication, and Transgene
Expression
(A) Melanoma cell lines were seeded and treated with VPA
(0, 1, and 2 mM) for 24 h prior to addition of HSVGM-CSF at
concentrations ranging from 0 to 1 PFUs/cell. Cells were left
for a further 48 h, and cell viability was determined by MTT
assay. The graph shows the average cell viability for at least
five independent experiments ± SEM. (B) VPA-treated
melanoma cells were treated with HSVGM-CSF for 24 h, and
GM-CSF production was determined by ELISA. The graph
shows the mean + SEM (n = 6). (C) MEL888 or A375 cells
were treated with 0.05 PFUs/cell HSVGM-CSF alone, 1 mM
VPA for 24 h prior to 0.05 PFUs/cell HSVGM-CSF, or 1 mM
VPA and 0.05 PFUs/cell HSVGM-CSF simultaneously. Cells
were left for 24 h, and the fold increase in HSVGM-CSF repli-
cation was determined by plaque assay. The graph shows
themean+SEM (n=4). Statistical significance isdenotedby
*p < 0.05, **p < 0.01, p*** < 0.005, and ****p < 0.0001.
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able sensitivity, and VPA signiﬁcantly increased the direct cytotoxic
effect of HSVGM-CSF in all cell lines tested (Figure 3A; Figure S4A).
Next, the ability of HSVGM-CSF to induce secretion of GM-CSF and
replicate in melanoma cells was determined. GM-CSF was produced
upon infection of all cell lines (Figure 3B; Figure S4B), although the
levels were lower in A375 cells compared with MEL888 cells (Fig-
ure 3A); signiﬁcantly, VPA increased GM-CSF secretion in both
the relatively resistant (A375) and sensitive (MEL888) cell lines
(Figure 3B). Additionally, plaque assays conﬁrmed the production
of infectious progeny virus and showed that VPA increased
HSVGM-CSF replication (Figure 3C), with potentiation by VPA being
most evident in A375 cells, which were inherently less permissive to
viral replication. In terms of scheduling of the two reagents,
and consistent with previous data,16 we also found that enhanced
HSVGM-CSF replication was dependent on pre-treatment with VPA;
otherwise, no increase in viral replication was seen (Figure 3C).
Importantly, HSVGM-CSF cytotoxicity against non-neoplastic human
foreskin ﬁbroblasts (HFFs) was not enhanced upon combination
with VPA (Figure S5), suggesting that VPA would not increase
off-target side effects caused by viremia in non-malignant tissue.6 Molecular Therapy Vol. 27 No 6 June 2019Collectively, these data conﬁrm that HSVGM-CSF
directly infects, kills, and replicates in human
melanoma cells, resulting in secretion of GM-
CSF, and that addition of VPA potentiates these
effects, particularly in cells that are otherwise
relatively poorly permissive.
HDAC Inhibition Augments HSVGM-CSF-
Induced Innate Anti-tumor Immunity
Having shown that VPA increases killing,
replication, and GM-CSF production upon
HSVGM-CSF treatment of human melanoma cells,
we next tested the effects of VPA on HSVGM-CSF-induced innate anti-tumor immunity. To address this, we ﬁrst tested
whether VPA affected the expression of activating NK ligands on hu-
manmelanoma cells; VPA has been reported previously to upregulate
NK ligand expression on acute myeloid leukemia cells in vivo.29,30We
observed upregulation of the NKG2D ligands MICA/B on MEL888
cells and MICA/B and ULBP2/5/6 on less permissive A375 cells
upon treatment with VPA (Figure 4A); similar results were also
observed using primary melanoma cells (Figure S6A and data not
shown). This suggested that addition of VPA could directly support
innate anti-tumor immunity by increasing activating NK cell:tumor
target interactions; this was subsequently conﬁrmed because
VPA treatment of melanoma cells prior to their co-culture with
HSVGM-CSF-treated PBMCs caused increased NK cell-mediated tu-
mor cell killing (Figure 4B). Importantly, additional studies have
conﬁrmed that alternative HDACIs also upregulate the expression
of NK cell-activating ligands on melanoma tumor cells (Figure S6B),
suggesting that the effects of VPA were due to HDAC inhibition and
not an alternative, HDAC-independent mechanism of action.
Furthermore, in line with previously published data that showed that
VPA was only toxic to NK cells at doses greater than 2.5 mM,31 we
Figure 4. VPA Augments HSVGM-CSF Innate
Anti-tumor Immunity
(A) Expression of NK ligands (MICA/B and ULBP2/5/6) on
the surface of melanoma cells was determined by flow
cytometry. Cells were treated with VPA at the indicated
doses for 48 h. Mean fluorescence intensity is shown +
SEM (n = 3). (B) Healthy donor PBMCs (untreated [0 PFUs]
or activated with HSVGM-CSF [0.001 or 0.01 PFUs] over-
night) were co-cultured with melanoma cells with or without
VPA for 5 h, and the percentage of target cell death was
determined by flow cytometry. The graph shows the
mean + SEM for at least four independent experiments.
Statistical significance is denoted by *p < 0.05, **p < 0.01,
and p*** < 0.005.
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HSVGM-CSF stimulation (e.g., the schedule required for enhanced
direct oncolysis) does not inhibit production of type I IFNa from
PBMCs (Figure S7A), which is necessary for NK cell activation;
furthermore, pre-treatment with VPA does not abrogate NK cell
CD107 degranulation against melanoma targets (Figure S7B). Collec-
tively, these data demonstrate that virus-activated NK cell effector
function combined with HDACi-induced upregulation of NK cell-
activating ligands could be used to potentiate the early, innate phase
of OV-mediated anti-tumor immunity.
HDACInhibition Enhances HSVGM-CSF-Mediated CTL Priming
against Human Melanoma
Having shown that HSVGM-CSF-treatedmelanoma cells can be used as
an “antigen load” for iDCs to prime the generation of CTLs (Fig-
ure 1F), we went on to examine the consequences of HDAC inhibition
for CTL priming. Moreover, to allow more complete characterization
of the CTL response, we developed an immune readout component to
allow tracking of T cell responses against a range of tumor-associated
antigens (TAAs) without human leukocyte antigen (HLA) restriction.
This adaptive immune readout involved pulsing autologous mono-
cytes (capable of antigen processing and presentation) with 15-mer
overlapping peptides of TAA (melanocyte protein PMEL [PMEL],
tyrosinase [TYR], and melanoma antigen recognized by T cells 1
[MART-1/MELAN-A]) and co-culturing these with CTLs. TAA pep-
tide recall responses by CTLs were then analyzed by ﬂow cytometry to
quantify intracellular IFNg production. As shown in Figure 5A,
HSVGM-CSF infection of MEL888 cells enhanced the CD8 response
against MEL888-expressed TAA, PMEL, MART-1, and TYR, with
signiﬁcant enhancement observed for MART-1 (p = 0.0028). More-
over, the quantity of TAA-speciﬁc responses measured against
PMEL and TYR was signiﬁcantly increased by co-treatment of
MEL888 cells with 2 mM VPA and HSVGM-CSF virus comparedwith HSVGM-CSF alone. Interestingly, MEL888
cells treated with 2 mM VPA prior to HSV infec-
tion and then co-cultured with iDCs had signiﬁ-
cantly reduced levels of IL-10 in cell culture
supernatants compared with virus-alone controls
(Figure 5B), and higher concentrations of IFNgwere detected in CTL culture supernatants (Figure 5C); thus, the
cytokine changes resulting from combination treatment may favor
the generation of TAA-speciﬁc CTLs.
As well as addressing whether VPA could boost the CD8 response
against TAAs expressed by melanoma cells, we also considered
whether HDAC inhibition might alter the expression of TAA by
melanoma cells and potentially broaden the range of antigens avail-
able for CTL priming. Initial studies demonstrated that VPA treat-
ment of MEL888 cells did not increase PMEL, MART-1, or TYR
expression at the protein level (data not shown). A375 cells do not
express PMEL under normal growth conditions; however, following
treatment with VPA or alternative HDACIs, signiﬁcant increases in
PMEL mRNA expression levels were detected (Figure 5D; Figure S8)
Moreover, using ﬂow cytometry and immunoﬂuorescence tech-
niques, we could detect PMEL protein expression following
VPA/HSVGM-CSF co-treatment but, interestingly, not following either
treatment alone (Figures 5Ei and 5Eii, respectively). Following these
observations, the ability of VPA to facilitate the generation of
PMEL-speciﬁc CTLs, using A375 cells as the antigen load, was
investigated. Figure 5F shows that only A375 cells treated with
VPA/HSVGM-CSF, but not virus alone, were capable of generating
PMEL-speciﬁc CTLs. Taken together, we have shown that
HSVGM-CSF infection supports human adaptive CTL priming against
a range of melanoma-associated TAAs and that this priming is
further increased by VPA, which can boost both the range and level
of responses against targeted epitopes.
DISCUSSION
OVs represent a promising class of novel cytotoxic and immunogenic
cancer therapy. Although T-Vec is the most clinically advanced agent,
there are few pre-clinical data to inform its future development and
optimal use, particularly in human systems. Despite its currentMolecular Therapy Vol. 27 No 6 June 2019 7
Figure 5. VPA Enhances HSVGM-CSF CTL Responses against Melanoma
(A–C) MEL888 cells were treated with the indicated doses of VPA for 24 h, followed by HSVGM-CSF (0.1 PFUs/cell) and co-cultured with iDCs for 24 h; non-adherent cells
(containing tumor-loaded APC) were removed and cultured with autologous PBMCs for 7 days. CTL cultures were re-stimulated appropriately and then used in TAA
peptide recall assays. (A) The graph shows themean (percent) of IFNg+ CD8+ T cells following the indicated peptide recall (n = 4). (B) Cell-free supernatants from VPA-treated,
HSVGM-CSF-infected MEL888 cells following co-culture with iDCs were collected, and the concentrations of IL-10 were determined by ELISA. The graph shows the mean +
SEM (n = 3). (C) Cell-free supernatants from CTL cultures were collected on day 14, and the concentrations of IFNgwere determined by ELISA. The graph shows the mean +
SEM (n = 4). (D–F) A375 cells were treated with the indicated doses of VPA for 24 h alone (D) or VPA followed by HSVGM-CSF at the indicated doses (E and F). (D) PMELmRNA
expression levels were quantified by qRT-PCR relative to the EF1a housekeeping control following treatment with VPA for 24 h (n = 6). (E) Intracellular protein expression of
PMEL was quantified by (i) flow cytometry (with or without VPA and/or with or without HSVGM-CSF; the graph shows the mean fluorescence intensity + SEM; n = 3) or (ii)
immunofluorescence (with or without VPA and 0.1 PFUs/cell HSVGM-CSF). (F) A375 cells were treated with the indicated doses of VPA for 24 h, followed by HSVGM-CSF
(0.1 PFUs/cell) and co-cultured with iDCs for 24 h. Non-adherent cells (containing tumor-loaded APC) were removed and cultured with autologous PBMCs for 7 days. CTL
cultures were re-stimulated appropriately and then used in a PMEL peptide recall assay. The graph shows the mean (percent) IFNg+ CD8+ T cells + SEM (n = 2). Statistical
significance is denoted by *p < 0.05 and **p < 0.01.
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Inhibition, Molecular Therapy (2019), https://doi.org/10.1016/j.ymthe.2019.04.008application as an intratumoral treatment for melanoma, initial mela-
noma studies were restricted to testing of a single cell line for cytotox-
icity in vitro only, using an early form of the virus that did not encode8 Molecular Therapy Vol. 27 No 6 June 2019GM-CSF.32 Therefore, in the current study, we sought to address the
role of both direct oncolysis and anti-tumor immunity (both innate
and adaptive) in T-Vec efﬁcacy using a closely related JS-1 strain of
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HDAC inhibition.
In our ﬁrst experiments, we extended our previous studies using the
dsRNA OV reovirus22,24–26 to test the potential of the DNA virus
HSVGM-CSF to stimulate innate and adaptive anti-melanoma immu-
nity (Figure 1). We found that (1) addition of HSVGM-CSF to human
PBMCs activated perforin and granzyme-mediated NK killing of mel-
anoma targets, (2) HSVGM-CSF induced maturation of iDCs, and (3)
HSVGM-CSF infection supported the generation of melanoma-speciﬁc
CTLs. This ability of HSVGM-CSF to activate innate and subsequent
adaptive anti-tumor immunity supports its designation as an immu-
notherapeutic agent in humans. At present, the consequences of
innate immune activation following administration of OVs remain
controversial. For example, murine models suggest that the innate
anti-viral NK cell response limits therapy by restricting direct tumor
oncolysis20,31,33,34 and viral replication and spread. Alternatively, NK
cells have been shown to be essential for the success of a number of
OVs across a range of pre-clinical models,35–39 suggesting that the
innate response to the virus is critical for therapy. Furthermore, for
other HSVs, experimental models have demonstrated the dependence
of intratumoral HSV-1-induced melanoma therapy on NK cells,40
and studies have described the effectiveness of UV-inactivated HSV
in stimulation of PBMCs to kill acute myeloid leukemia tumor cells
in the absence of direct oncolysis.41 These lines of evidence support
a positive role of the innate response in HSV therapy.
Currently, clinical use of T-Vec is restricted to intratumoral delivery;
however, we know that the virus is subsequently released systemically
because it can be detected in the circulation and in lymph nodes.5,10
This viremia, which is consistent with transient ﬂu-like symptoms
and induction of an anti-viral antibody response, means that the virus
has the potential to activate anti-tumor immunity systemically as well
as locally in the tumor. Therefore, our study of the human innate ef-
fects of HSVGM-CSF on PBMCs as well as on infected melanoma cells
as the antigen load in a CTL priming assay remains clinically relevant.
However, it is also important to note that HSV will initially engage an
immunologically suppressive TME comprising Tregs, myeloid-
derived suppressor cells (MDSCs), and M2-polarized macrophages;
however, despite this, HSV has the capacity to modulate the TME4
to enrich levels of melanoma-speciﬁc effector T cells and decrease
levels of Tregs at the site of tumor viral injection.7 Interestingly,
HSV has been reported to inactivate MDSCs,42 and it is possible
that HSV injection could increase NK cell inﬁltration at the tumor
site, as described for alternative OVs,43 but this remains undescribed
for T-Vec.
The work illustrated is especially important because the effects
described here cannot be reliably modeled in murine systems. In
particular, we tried testing HSVGM-CSF alone or in combination
with VPA inmurine in vitro and in vivo systems but found that mouse
tumor cells (e.g., B16 melanoma cells) were far more resistant to
HSVGM-CSF than human melanoma cells, and VPA was unable to in-
crease NK cell-activating ligands on murine melanoma cells. Nomeaningful comparative results could be obtained in murine models,
and we believe that this was due to major inherent differences be-
tween human melanoma models and murine immunocompetent
models (in particular, only humans are natural hosts for type I
HSV) rather than any lack of potential combination therapeutic
beneﬁt to patients.
In terms of the mechanisms by which HSV activates a human im-
mune response, we found, as with reovirus,24 that production of
type I IFNs, mediated by monocytes, was required (Figure 2). Howev-
er, these innate responses are not identical for all OVs; for example,
monocytes are not required for IFN production induced by ssRNA
coxsackievirus (unpublished data), and the IFNg and IL-29 secretion
we observed in response to HSVGM-CSF (Figure 2C) was not seen with
reovirus.22,44 The detailed mechanisms by which viral detector cells
respond to ssRNA, dsRNA, and DNA viruses and how these shape
the ensuing adaptive immune response are worthy of further study
and are likely to inform the development of optimally immunogenic
virotherapy, particularly as part of combination strategies. However,
despite the clear role of monocytes in type I IFN production and sub-
sequent NK cell activation, NK cells were still activated (although to a
lesser extent) in the absence of monocytes, and low-level IFNa pro-
duction was still observed. Therefore, it is possible that alternative
mechanisms may also be involved in the detection of HSV; for
example, plasmacytoid DCs have also been reported to play a role
in regulating anti-HSV immune responses.45–47
Among the various immunomodulatory strategies tested in combina-
tion with OVs, HDACIs have been explored as a means to enhance
virus-mediated oncolysis via suppression of the tumor cell anti-viral
IFN response following infection.16,31 However, HDAC inhibition
has a wide range of consequences, and a recent study demonstrated,
using cDNA arrays, that the expression of 10%–20% of genes was
altered following treatment with HDACIs.48 We found that pre-treat-
ment of human melanoma cell lines with VPA increased cytotoxicity,
GM-CSF secretion, and viral replication upon infection with
HSVGM-CSF (Figure 3), although no effect of HDACi on IFN produc-
tion or expression of IFN-stimulated genes by tumor cells was
observed following virus infection (data not shown). In fact, we
were unable to detect IFNa, IFNb, IL-28a, or IL-28b/IL-29 by ELISA
following HSVGM-CSF, and gene expression results conﬁrmed that
viral treatment did not induce an IFN signaling cascade (data not
shown). Moreover, we also explored the possibility that VPA could
alter the surface expression of the HSV receptors HVEM and Nectin
1 or alter NF-kB signaling;49 no changes were observed following
VPA treatment (data not shown). Currently the mechanisms respon-
sible for enhanced HSVGM-CSF-induced direct oncolysis following
VPA treatment remain to be fully elucidated; however, an alternative
mechanism could be that VPA alteration of chromatin structure pre-
vents HSVGM-CSF from “hiding” within DNA, making it more acces-
sible for viral replication.50
Perhaps more importantly, from an immune perspective, we
found that HDACIs upregulated expression of NKG2D ligands onMolecular Therapy Vol. 27 No 6 June 2019 9
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activated PBMCs (Figure 4). Furthermore, in a novel assay that
quantiﬁed non-HLA-restricted anti-TAA CTL priming, addition
of HDACIs to HSVGM-CSF treatment of melanoma cells enhanced
both the magnitude and range of TAAs expressed by tumor cells
as targets for CD8 T cell recognition (Figure 5). Although it was un-
expected that PMEL expression was only observed at the protein
level upon co-treatment of VPA and HSVGM-CSF, because HSV
infection is usually associated with “shutoff” of host protein trans-
lation to limit viral detection and allow propagation,51,52 the balance
between histone acetylation or deacetylation is important for HSV
propagation.53 Therefore, it is possible that HDAC inhibition by
VPA allows transcription of PMEL mRNA for subsequent process-
ing in HSV-infected cells, where HSV will employ a range of stra-
tegies to stimulate viral protein synthesis, including enhancement
of translation initiation and prevention of translation shutdown
following cell stress.52 We are currently investigating whether the
expanded range of antigens recognized by primed CTLs in combi-
nation VPA/HSVGM-CSF treatment extends to neoantigens as well
as the shared, non-mutated TAAs we have tracked here and
whether this is reﬂected in the T cell receptor repertoire, which de-
velops over time. Importantly, in terms of clinical application of
VPA with HSVGM-CSF, the doses of VPA used to potentiate direct
oncolysis and anti-tumor immunity would be clinically achievable,
with current therapeutic ranges for epilepsy and mania ranging be-
tween 20–125 mg/L (0.15–0.87 mM), only marginally lower than
the doses utilized in this study; higher serum concentrations are
clinically achievable with appropriate monitoring for additional
toxicity.54,55
In summary, we have shown, using clinically relevant human pre-
clinical models of innate and adaptive anti-tumor immune priming,
that HSVGM-CSF is capable of activating an anti-melanoma immune
response and that the cytotoxicity and immunogenicity of the
currently most clinically advanced class of OV is further boosted by
combination with HDAC inhibition. These data provide a platform
to explore further OV and immunotherapy combination strategies
in human pre-clinical systems and support incorporation of clinical
HDACIs into future HSV-based OV clinical trials.MATERIALS AND METHODS
Cell Culture and Reagents
The A375, MeWo, and Vero cell lines were purchased from the ATCC
and authenticated using short tandem repeat (STR) proﬁling and
comparison with the DSMZ database. MEL88856 and MM9657 cells
were obtained from the Cancer Research UK cell bank, and MCF-7
cells were kindly provided by M. Muthana (Department of Oncology
andMetabolism, University of Shefﬁeld). In the absence of a reference
proﬁle in the DSMZ database, cell lines were shown to have an orig-
inal STR proﬁle that was distinct from all other cell lines in the data-
base. HFFs were also purchased from the ATCC. All cell lines and
HFFs were grown in glutamine-containing DMEM (Sigma-Aldrich)
supplemented with 10% fetal calf serum (FCS) (v/v) (Biosera). All10 Molecular Therapy Vol. 27 No 6 June 2019cell lines were routinely checked for mycoplasma and were free
from contamination.
PBMCs were isolated from healthy donor volunteers or melanoma
patients after written informed consent was obtained in accordance
with local institutional ethics and review approval (06/Q1206/106).
PBMCs were isolated from whole blood by density gradient centrifu-
gation on Lymphoprep (Aldere) and cultured at 2  106 cells/mL in
glutamine-containing RPMI medium (Sigma-Aldrich) supplemented
with 10% FCS (v/v). Where indicated, NK cells were freshly isolated,
or CD14+ cells were removed or isolated from PBMCs using MACS
isolation procedures, following the manufacturer’s protocols (Milte-
nyi Biotec). iDCs were generated by culturing CD14+ cells in gluta-
mine-containing RPMI medium supplemented with 10% FCS (v/v),
recombinant human IL-4 (500 IU/mL), and GM-CSF (800 IU/mL)
(both from R&D Systems) at a cell density of 1–2  106 cells/mL
for 5 days. CTLs were cultured at 4 106 cells/mL in glutamine-con-
taining RPMI medium supplemented with 7.5% (v/v) human AB
serum, 1 mM sodium pyruvate, 1 mMHEPES, 1% (v/v) non-essential
amino acids, 20 mM 2b-mercaptoethanol (all from Sigma-Aldrich)
and recombinant human IL-7 (5 ng/mL) (Miltenyi Biotec). VPA
(Sigma-Aldrich) was added to cell cultures at 0, 1, or 2 mM for the
indicated durations.Viruses
JS1 34.5-human GM-CSF (hGM-CSF) 47-pA+ (HSVGM-CSF) was
kindly provided by Amgen, and the virus titer was determined by a
standard plaque assay on Vero cells. The JS1 34.5-hGM-CSF
47-pA+ used in these studies differs from the clinical agent
tamilogene laherparepvec in that the US11 gene is not under control
of the ICP47 intermediate-early promoter because of the addition of a
poly(A) sequence between the promotor and the US11 coding
sequence.HSVGM-CSF Replication
Cells were treated with HSVGM-CSF alone, HSVGM-CSF following 24-h
pre-treatment with VPA, or VPA/HSVGM-CSF simultaneously. Cells
and supernatants were harvested and subjected to three rounds of
freezing and thawing using a 37C water bath and methanol and
dry ice. HSVGM-CSF concentration was determined by standard pla-
que assay on Vero cells, and the fold increase in virus titer was deter-
mined by comparison with the input virus.MTT Cell Viability
Melanoma cell lines were seeded at 8  103 cells/well into 96-well
plates and left to adhere overnight. Cells were treated with
HSVGM-CSF at the indicated doses for 48 h (with or without pre-treat-
ment with VPA for 24 h). 20 mLMTT (5 mg/mL, Sigma-Aldrich) was
added to cells 4 h prior to the end of the incubation period before the
tissue culture supernatant was removed, and cells were solubilized
using 150 mL DMSO (Sigma-Aldrich). Optical density absorbance
readings were determined using a Thermo Multiskan EX plate reader
(Thermo Fisher Scientiﬁc) at 540 nm absorbance.
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The production of human GM-CSF, IFNa (both from Mabtech),
IFNb (PBL Interferon Source), IL-10, TNF-a, IFNg (all from BD
Pharmingen) and IL-29 (R&D Systems) in cell-free supernatant was
determined using matched-paired antibodies according to the manu-
facturers’ instructions. Optical density absorbance readings were
determined using a Thermo Multiskan EX plate reader (Thermo
Fisher Scientiﬁc) at 405 nm absorbance.
Cell Surface Phenotyping
Cell surface expression of the indicated markers was quantiﬁed by
ﬂow cytometry. Brieﬂy, cells were harvested, washed in ﬂuores-
cence-activated cell sorting (FACS) buffer (PBS, 1% [v/v] FCS, and
0.1% [w/v] sodium azide), and incubated for 30 min at 4C with spe-
ciﬁc antibodies or matching isotype controls. Cells were washed with
FACS buffer and then ﬁxed with 1% paraformaldehyde (PFA) (1%
[w/v] PFA in PBS) and stored at 4C prior to acquisition. Flow cytom-
etry analysis was performed either using a FACSCalibur (and analysis
was carried out using Cell Quest Pro software; BD Biosciences), an
Attune ﬂow cytometer (Life Technologies, with analysis performed
on its accompanying software), or a CytoFLEX S (Beckman Coulter;
analysis carried out using CytExpert software).
Intracellular Staining
Cells were cell surface-stained and ﬁxed overnight with 1% PFA prior
to permeabilization with 0.3% saponin (Sigma-Aldrich) for 15 min at
4C. Cells were washed with 0.1% saponin and incubated with speciﬁc
antibodies or matched isotype controls for 30 min at 4C. If the
primary antibody was ﬂuorescently-unconjugated, then cells were
incubated with a matched ﬂuorescently conjugated antibody for
30 min at 4C. Cells were washed with PBS, and ﬂow cytometry anal-
ysis was performed immediately using a CytoFLEX S.
Flow Cytometry Antibodies
The following ﬂow cytometry antibodies were used: CD11c APC-
Vio770 (MJ4-27G12, Miltenyi Biotec), CD14-PerCP (TUK4,Miltenyi
Biotec), CD86-phycoerythrin (PE)-Cy7 (2331, BD Biosciences),
CD80-PE (L307.4, BD Biosciences), HLA-ABC-VioBlue (REA230,
Miltenyi Biotec), HLA-DR/DP/DQ-ﬂuorescein isothiocyanate
(FITC) (Tu39, BD Biosciences), CD3-PerCP (SK7, BD Biosciences),
CD56-PE (B159, BD Biosciences), CD8-APC (RPA-T8, BD Biosci-
ences) CD107a-FITC (H4A3, BD Biosciences), CD107b-FITC
(H4B4, BD Biosciences), CD69-FITC (FN50, BD Biosciences),
MICA/B-PE (6D4, BD Biosciences), ULBP2/5/6 (FAB1298p, R&D
Systems), IFNg-BV421 (4S.B3, BD Biosciences), mouse immuno-
globulin G1 (IgG1) k isotype control (PE/FITC/PerCP/PE-Cy7/
APC; MOPC-21, BD Biosciences), mouse IgG2a k isotype control
(FITC/PE; G155-178, BD Biosciences), and REA Control-VioBlue
(REA293, Miltenyi Biotec).
CD107a/b NK Cell Degranulation Assay
Healthy donor or melanoma patient PBMCs were treated with
HSVGM-CSF overnight and co-cultured with melanoma cell targets
at a 10:1 ratio for 1 h at 37C. 10 mg/mL Brefeldin A (BioLegend),anti-CD107a/b, anti-CD3, and anti-CD56 were added for a further
4 h at 37C before cells were washed with FACS buffer and ﬁxed using
1% PFA. Flow cytometry analysis was performed using either the
Attune or CytoFLEX S ﬂow cytometers.
Flow Cytometry Killing Assay
Healthy donor PBMCs were activated with HSVGM-CSF overnight at
the indicated concentrations, and their ability to kill melanoma cell
targets (with or without VPA treatment) stained with Cell Tracker
Green (Molecular Probes) was determined using standard 5-h co-cul-
ture. Co-cultures were washed and stained for viability using a live-
dead ﬁxable dead cell stain (Thermo Fisher Scientiﬁc) before analysis
using an Attune ﬂow cytometer.
Neutralization of Type I IFNs
PBMCs were treated with HSVGM-CSF overnight in the presence or
absence of neutralizing antibodies (IFN Block, PBL Interferon
Source) or an isotype control (IFN Isotype, R&D Systems). The
IFN block consisted of sheep polyclonal anti-human IFN-a, sheep
polyclonal anti-human IFN-b (both used at 1.5%), and mouse mono-
clonal anti-human IFN-a/b receptor chain 2 (used at 2.5%), as
described previously.22 The isotype control consisted of sheep serum
(Sigma-Aldrich) used at 3% and mouse IgG2a used at 2.5%. PBMCs
were then washed and used in CD107 degranulation assays, 51Cr cyto-
toxicity assays, or stained for cell surface expression of CD69 as
described above.
Real-Time qPCR
Total RNA from cells was isolated using TRiZol (Invitrogen), and
1 mg of RNA was used to synthesize cDNA using Maxima Reverse
Transcriptase (Thermo Fisher Scientiﬁc) according to the manufac-
turer’s instructions. Real-time qPCR was carried out with SYBR
Green mix (Applied Biosciences) using a QuantStudio5 real-time
PCR system (Thermo Fisher Scientiﬁc). Primer sequences were
as follows: PMEL-F (50-TATCATGCCTGTGCCTGGGA-30) and
PMEL-R (50-GGGGTACGGAGAAGTCTTGC-30) for PMEL and
EIFA-F (50-GATTACAGGGACATCTCAAGGCG-30) and EIFA-R
(50-TATCTCTTCTGGCTGTAGGGTGG-30) for the EIFA house-
keeping control.
Immunofluorescence
Cells were ﬁxed with 4% PFA and permeabilized with 0.1% Triton
X-100 (Sigma-Aldrich). Samples were incubated with anti-melanoma
PMEL antibody (gp100) at a dilution of 1/250 (EP4863 [2], Abcam),
followed by goat anti-rabbit IgG (Alexa Fluor 488, Abcam) secondary
antibody, following the manufacturer’s instructions. Cells were then
imaged using the EVOS imaging system (Thermo Fisher Scientiﬁc).
Cytotoxic T Cell Priming Assay
Melanoma cells were treated with or without VPA 24 h prior to
addition of HSVGM-CSF and iDCs. Non-adherent cells (iDCs loaded
with TAA) were removed 24 h after addition of HSVGM-CSF and
cultured with autologous PBMCs for 7 days. CTLs were re-stimulated
(as previously) and cultured for a further 7 days. Primed CTLs wereMolecular Therapy Vol. 27 No 6 June 2019 11
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assays.51Cr Release Assay
HSVGM-CSF-treated PBMCs (with or without NK cell depletion) or
CTLs were co-cultured with 51Cr (PerkinElmer)-labeled MEL888,
A375, MeWo, or MCF-7 cells at different effector:target (E:T) ratios
for 4 h (with or without 2 mM EGTA where indicated). Cells were
then pelleted by centrifugation, and 50 mL of supernatant was trans-
ferred to scintillation plates (PerkinElmer) prior to analysis using a
Wallac Jet 1459 Microbeta scintillation counter and Microbeta Win-
dows software (PerkinElmer). Tumor cell percentage lysis was deter-
mined using the following calculation.
% lysis= ðSample CPM  Spontaneous CPMÞ=
ðMaximum CPM  Spontaneous CPMÞ  100
Peptide Recall Assay
To measure peptide-speciﬁc CTL responses, autologous CD14+ cells
were incubated with the PMEL, TYR, or MART-1/MELAN-A
PepTivator peptide pools (15-mer peptide sequences with 11-amino
acid overlap, Miltenyi Biotec) for 60 min at 37C according to the
manufacturer’s instructions. Autologous CD14+ cells with or without
peptide labeling were then co-cultured with CTLs for 60 min at 37C
before addition of Brefeldin A (1:1,000, BioLegend) and an anti-CD8-
APC antibody for identiﬁcation of CTLs. CTLs were then incubated
for a further 4 h at 37C, and cells were ﬁxed prior to intracellular
IFNg staining and acquisition and analysis by ﬂow cytometry.Statistical Significance
Statistical analysis was carried out with the GraphPad Prism software.
Statistical differences among groups were determined using Student’s
t test, one-way ANOVA, or two-way ANOVA. The criterion for sta-
tistical signiﬁcance was p value of less than 0.05.SUPPLEMENTAL INFORMATION
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